{
  "doi": "10.1016/j.ijcard.2014.07.106",
  "full_text": "InternationalJournalofCardiology176(2014)1113\u20131115\nContentslistsavailableatScienceDirect\nInternational Journal of Cardiology\njournal homepage: www.elsevier.com/locate/ijcard\nLettertotheEditor\nEvaluationoftheclinicaluseofmidregionalpro-atrialnatriureticpeptide\n(MR-proANP) in comparison to N-terminal pro-B-type natriuretic\npeptide (NT-proBNP) for risk stratification in patients with\nlight-chain amyloidosis\nArntV.Kristena,\u204e ,MoritzBienera,UteHegenbartb,StefanHardta,PhilippA.Schnabelc,ChristophR\u00f6ckend,\nStefanO.Schonlandb,HugoA.Katusa,EvangelosGiannitsisa\naDepartmentofCardiology,Angiology,andRespiratoryMedicine,HeidelbergUniversity,ImNeuenheimerFeld410,D-69120Heidelberg,Germany\nbDepartmentofHaematologyandOncology,HeidelbergUniversity,ImNeuenheimerFeld410,D-69120Heidelberg,Germany\ncInstituteofPathology,HeidelbergUniversity,ImNeuenheimerFeld220/221,D-69120Heidelberg,Germany\ndInstituteofPathology,KielUniversity,Arnold-Heller-Stra\u00dfe3/14,D-24105Kiel,Germany\na r t i c l e i n f o\nRocheDiagnostics,Germany),high-sensitivity troponin-T (Elecsys-\n2010,RocheDiagnostics,Germany),andMR-proANP.Moreover,12-\nArticlehistory:\nReceived11February2014 leadelectrocardiographyandechocardiographywereperformed.Cardi-\nReceivedinrevisedform13July2014 acinvolvementwasdefinedeitherbyendomyocardialbiopsy(n=39)\nAccepted26July2014 orbymeanleftventricularwallthicknessN12mmandNT-proBNP\nAvailableonline1August2014 N332ng/L(n=77)inpatientswithnormalkidneyfunctionandhisto-\nlogicallyprovenextra-cardiacamyloidosis[7].\nKeywords:\nAtrialnatriureticpeptide Continuousdatawereexpressedasmean\u00b1standarddeviation\nBiomarkers (two-tailedMann\u2013Whitney-test).Categoricalvariableswereabso-\nLight-chainamyloidosis lute number and percent (\u03c72-test). Correlation analyses were\nN-terminalbrain-typenatriureticpeptide performedusingSpearman'scoefficient.Cut-offvaluesweredeter-\nSurvival\nTroponinT\nminedbyROCanalyses.Kaplan\u2013Meiercurveswereanalyzedusing\nlog-rank analysis with right-censoring. Univariate and stepwise\nmultivariateCoxregressionmodelswereusedforassessmentof\npredictors of survival (eligibility for future autologous stem cell\ntransplantation), difference between involved/uninvolved free\nTheextentofcardiacinvolvementisthemostimportantdetermi- light-chains (dFLC), mitral annular systolic velocity, NT-proBNP,\nnantofclinicaloutcomeinlight-chainamyloidosis(AL)troponinT MR-proANP,andhigh-sensitivitytroponin-T.pb0.05wasconsid-\nandN-terminalpro-B-typenatriuretic-peptide(NT-proBNP)provide ered statistically significant. All analyses were performed using\npotentprognosticinformation[1,2]andwereincorporatedinawidely SPSS(Version21,IBM-Corporation).\nusedclassificationsystem[3].BesidesNT-proBNP,atrialnatriureticpep- Typeoflight-chainswaslambdain148(80%)patientsandkappain\ntide(ANP)isincreasedinheartfailure. 37(20%)patients.Meannumberofinvolvedorganswas2.6\u00b10.1in-\nAnovelsandwichimmunoassaydetectsthemorestablemid- cludingrenalinvolvementin112(61%)patientsestimatedglomerular\nregionalsequenceofpro-atrialnatriuretic-peptide(MR-proANP- filtrationrate70.1\u00b12.9mL/min\u22171.73m2).MeandFLCwas325.3\u00b1\nLIA,B.R.A.H.M.S.GmbH,Germany)[4].Thediagnosticrangeofthis 3.1mg/L.Duringfollow-up43(23%)patientswereeligibleforautolo-\nassayis3\u20131000pmol/L.MR-proANPisanindependentpredictorof gousstemcelltransplantation.\nmortalityinchronicheartfailure[5]comparabletoresultsobtained Cardiac biomarkers were markedly elevated (hs-TnT 72.5 \u00b1\nwithNT-proBNP[6].ThepotentialroleofMR-proANPinALhasnot 7.2pg/mL; NT-proBNP 7473 \u00b1 1055ng/L; MR-proANP 319 \u00b1\nbeeninvestigated. 18pmol/L).CorrelationsoflogNT-proBNPandlogMR-proANP(r=\nThisstudycomprises185ALpatients(111males,74females,mean 0.748;pb0.001),estimatedglomerularfiltrationrateandlogMR-\nage61.2\u00b10.7years)assessedattheirinitialevaluationatHeidelberg proANP (r = \u22120.682; p b0.001) as well as logNT-proBNP (r =\nAmyloidosisCenter.Allpatientshadbiopsy-provenAL(Congored; 0.445,pb0.001)wereobserved.PlasmalevelsofNT-proBNPwere\nimmunohistochemistry). Standard blood tests included serum free higherinthepresenceofcardiacinvolvement(7454\u00b1882ng/L)\nlight-chaintest(Binding-Site,Germany),NT-proBNP(Elecsys-proBNP, thaninpatientswithout(2051\u00b1971ng/L;pb0.01).Similarfind-\ningswereobservedforMR-proANP(373\u00b123pmol/Lvs.244\u00b1\n\u204e Correspondingauthor. 45pmol/L;pb0.01).PlasmalevelsofNT-proBNPandMR-proANP\nhttp://dx.doi.org/10.1016/j.ijcard.2014.07.106\n0167-5273/\u00a92014ElsevierIrelandLtd.Allrightsreserved.\n1114 A.V.Kristenetal./InternationalJournalofCardiology176(2014)1113\u20131115\nTable1\nPlasmalevelsofNT-proBNPandMR-proANPaccordingtovariousindicatorsofseverityof(cardiac)disease.\nNT-proBNP(ng/L) MR-proANP(pmol/L)\n\u2264Cut-off NCut-off \u2264Cut-off NCut-off\n\u204e\u204e\u204e \u204e\u204e\u204e\nNumberoforgansinvolved(cut-off2) 2980\u00b1770 8377\u00b11246 246\u00b135 334\u00b120\nGlomerularfiltrationrate 12,908\u00b12194 3369\u00b1567\u204e\u204e\u204e 488\u00b129 195\u00b111\u204e\u204e\u204e\n(cut-off60mL/min\u22171.73m2)\n\u204e\u204e\u204e \u204e\u204e\u204e\nNYHA(cut-offNYHAII) 4379\u00b1825 12,858\u00b12413 275\u00b123 406\u00b128\n\u204e\u204e \u204e\nQRSwidth 5823\u00b1765 19,888\u00b16419 299\u00b118 463\u00b162\n(cut-off120ms)\n\u204e\u204e\u204e \u204e\u204e\u204e\nSeptalthickness 4947\u00b11203 10,845\u00b11853 298\u00b127 364\u00b125\n(cut-off15mm)\n\u204e\u204e\u204e \u204e\u204e\nLowvoltagepattern 5262\u00b11100 10,863\u00b12120 283\u00b121 403\u00b132\n(novs.yes)\n\u204e\u204e\u204e \u204e\u204e\u204e\nLeftatrialdiameter 4932\u00b11029 11,476\u00b12089 282\u00b123 393\u00b129\n(cut-off40mm)\n\u204e\u204e\u204e \u204e\u204e\u204e\nEligibleforautologousstemcelltransplant(yesvs.no) 2695\u00b1771 8862\u00b11320 218\u00b1323 49\u00b120\n\u204e\u204e\u204e \u204e\u204e\u204e\nMitralannularsystolicvelocity(cut-off6cm/s) 10,648\u00b12058 3815\u00b1819 347\u00b125 289\u00b128\nDataaremean\u00b1SEM.\n\u204e pb0.05.\n\u204e\u204e pb0.001.\n\u204e\u204e\u204e pb0.001.\nwere higher at patients with more advanced (cardiac) disease\nA\n(Table1).\nDuringfollow-upof28\u00b12months84patientsdied.Overall1-/2-\nyearsurvivalwas77.0/65.8%,respectively.Survivorshadlowerplas-\nMR-proANP\nmalevelsofNT-proBNP(4453\u00b1712ng/Lvs.10,966\u00b12063ng/L;\nNT-proBNP\npb0.001)andMR-proANP(285\u00b122pmol/Lvs.360\u00b127pmol/L;\npb0.05)thandeceasedpatients.Optimalprognosticaccuracyof\nMR-proANPregardingsurvivalwasobtainedat139.8pmol/L(AUC\n0.607;95%CI0.527\u20130.688;p=0.012).Cut-offofNT-proBNPwas\n1016.5ng/L(AUC0.685;95%CI0.609\u20130.762;pb0.001).Patients\nwithMR-proANPabovethecut-offhadasignificantshortersurvival\nthansubjectsbelowthecut-off(logrank8.007;pb0.01).Survivalof\npatientsstratifiedbyplasmalevelsofhs-TnT(cut-off50pg/mL)\nand MR-proANP (cut-off 139.8pmol/L) revealed three different\nrisk groups as demonstrated previously for troponin T and NT-\nproBNP[3].Kaplan\u2013Meiercurvesoftheestablishedandthemodi-\nfiedmodelwerecomparable(Fig.1).\nUnivariatepredictorsofsurvivalwereNT-proBNP(pb0.001;HR\n1.000;95%CI1.000\u20131.000),hs-TnT(pb0.001;HR1.004;95%CI1.003\u2013 1-sensitivity\n1.006),MR-proANP(pb0.001;HR1.001;95%CI1.001\u20131.002),lambda\nB\nlight-chain(pb0.05;HR10.469;95%CI1.384\u201379.579),ineligibilityfor\nfuture autologous stem cell transplantation (p b0.001;HR 3.266; 100\n95%CI 1.759\u20136.065), heart failure NYHA I/II (p b0.001;HR 0.329;\n95%CI 0.206\u20130.526), dFLC (p b0.01;HR 1.000; 95%CI 1.000\u20131.000),\n80\nabsence of low voltage pattern (p b0.01;HR 0.505; 95%CI 0.318\u2013\n0.802),thicknessoftheinterventricularseptum(pb0.001;HR1.103,\n95%CI1.047\u20131.163),sustainedmitralannularplanesystolicexcursion 60\n(pb0.001;HR0.767;95%CI0.687\u20130.855),and left atrial diameter\n(pb0.001;HR1.080;95%CI1.040\u20131.122).Amultivariablemodelre-\n40\nvealedhs-TnT(pb0.001;HR1.004)andmitralannularplanesystolic\nexcursion(pb0.001;HR0.188)asindependentdeterminantsofmor-\ntality,butnotNT-proBNPorMR-proANP.Netreclassificationindexre- 20 p<0.001, logrank 21.798\nstage I: MR-proANP <139.8 pmol/ L and hs-TnT<50 pg/mL (n=42)\nvealednodifferencebetweenthetraditionalmodelincludinghs-TnT\nstage II: MR-proANP <139.8 pmol/L or hs-TnT<50 pg/mL (n=66)\nandNT-proBNPandthemodelincludinghs-TnTandMR-proANP. 0 stage III: MR-proANP \u2265139.8 pmol/L and hs-TnT \u2265 50 pg/mL (n=77)\nMarkedlyelevatedplasmalevelsofMR-proANPwereobservedinAL\n0 10 20 30 40 50 60 70 80\npatientsascomparedwithhealthycontrols[4].MR-proANPwasassoci-\ntime (months)\natedwiththeextentofcardiacinvolvementandmortality.Thevalueof\ntroponinTandNT-proBNPpredictingmortalitywasconfirmed;howev- number at risk\nstage I 42 28 16 10 0\nerthisobservationwasindependentoftheuseofeitherNT-proBNPor\nMR-proANP. stage II 66 40 16 8 0\nThediagnosticperformanceofMR-proANPwascomparablewith stage III 77 32 13 7 0\nNT-proBNPinacuteheartfailure[8],andatrialfibrillation[9].MR-\nFig.1.RiskstratificationofpatientswithALamyloidosis.Comparisonofreceiveroperating\nproANPalsoemergedasapredictoroffuturecardiovasculareventsin\ncharacteristiccurvesforMR-proANPandNT-proBnPinALamyloidosis(A)andassociation\npatientswithsuspectedacutecoronarysyndrome[10],patientswith\nofhigh-sensitivitytroponinandMR-proANPplasmalevelswithsurvivalinpatientswith\nacute [9], and chronic heart failure [5], and acute stroke [11]. The ALamyloidosis(B).\nyticificeps\n)%(\nlavivrus\nevitalumuc\nA.V.Kristenetal./InternationalJournalofCardiology176(2014)1113\u20131115 1115\npresentdatademonstratethatplasmalevelsofMR-proANPreflectse- [2] DispenzieriA,KyleRA,GertzMA,etal.Survivalinpatientswithprimarysystemic\namyloidosisandraisedserumcardiactroponins.Lancet2003;361(9371):1787\u20139.\nverityofcardiacinvolvementinAL.InALmultiplealternativevariables\n[3] DispenzieriA,GertzMA,KyleRA,etal.SerumcardiactroponinsandN-terminalpro-\nbasedoneitherechocardiographyorelectrocardiographyhavebeenad- brainnatriureticpeptide:astagingsystemforprimarysystemicamyloidosis.JClin\nvocated[12,13].However,themostpowerfulstagingsysteminclinical Oncol2004;22(18):3751\u20137.\n[4] MorgenthalerNG,StruckJ,AlonsoC,BergmannA.Measurementofmidregional\nroutineemploysplasmalevelsofcardiacbiomarkers(NT-proBNP,tro-\nproadrenomedullininplasmawithanimmunoluminometricassay.ClinChem\nponin).Inthepresentstudyabiomarkerdrivenstagingsystembased 2005;51(10):1823\u20139.\nonNT-proBNPandtroponinT[3]allowedadiscriminationbetween [5] HaehlingvonS,JankowskaEA,MorgenthalerNG,etal.Comparisonofmidregional\nlow,intermediate,andhighriskpatients.Interestingly,thesamedis- pro-atrialnatriureticpeptidewithN-terminalpro-B-typenatriureticpeptidein\npredictingsurvivalinpatientswithchronicheartfailure.JAmCollCardiol2007;\ncriminationwasobtainedforthemodifiedsystem.Netreclassification\n50(20):1973\u201380.\nindexrevealednostatisticalsignificantdifference. [6] PalladiniG,FoliA,MilaniP,etal.BestuseofcardiacbiomarkersinpatientswithAL\nInconclusion,inALNT-proBNPandMR-proANPprovidedsimilar\namyloidosisandrenalfailure.AmJHematol2012;87(5):465\u201371.\n[7] FelkerGM.Natriureticpeptidesinthediagnosisandmanagementofheartfailure.\nresults regarding severity of cardiac disease and prognostic power CanMedAssocJ2006;175(6):611\u20137.\nwhencombinedwithtroponinT. [8] SerondeM-F,GayatE,LogeartD,etal.Comparisonofthediagnosticandprognostic\nvaluesofB-typeandatrial-typenatriureticpeptidesinacuteheartfailure.IntJ\nConflictofinterest\nCardiol2013;168(4):3404\u201311.\n[9] EcksteinJ,PotockiM,MurrayK,etal.Directcomparisonofmid-regionalpro-atrial\nnatriureticpeptidewithN-terminalproB-typenatriureticpeptideinthediagnosis\nEGhasreceivedfinancialsupportforclinicaltrialsfromRocheDiag- ofpatientswithatrialfibrillationanddyspnoea.Heart2012;98(20):1518\u201322.\n[10] TzikasS,KellerT,OjedaFM,etal.MR-proANPandMR-proADMforriskstratification\nnostics,Germany,andBRAHMS,Germany.HeisconsultanttoRocheDi- ofpatientswithacutechestpain.Heart2013;99(6):388\u201395.\nagnosticsandBRAHMS,Germany.Hereceiveshonorariaforlectures [11] KatanM,FluriF,SchuetzP,etal.Midregionalpro-atrialnatriureticpeptideandout-\nfromRocheDiagnosticsandBRAHMS.HAKhasdevelopedthetroponin comeinpatientswithacuteischemicstroke.JAmCollCardiol2010;56(13):\n1045\u201353.\nTassayandholdsapatentjointlywithRocheDiagnostics.Hehasre-\n[12] BussSJ,EmamiM,MerelesD,etal.LongitudinalLeftventricularfunctionforpredic-\nceivedhonorariaforlecturesfromRocheDiagnostics. tionofsurvivalinsystemiclight-chainamyloidosis.JAmCollCardiol2012;60(12):\n1067\u201376.\nReferences [13] KristenA,PerzJ,Sch\u00f6nlandS,etal.Non-invasivepredictorsofsurvivalincardiac\namyloidosis.EurJHeartFail2007;9(6\u20137):617\u201324.\n[1] PalladiniG,CampanaC,KlersyC,etal.SerumN-Terminalpro-brainnatriureticpep-\ntideisasensitivemarkerofmyocardialdysfunctioninALamyloidosis.Circulation\n2003;107(19):2440\u20135.",
  "source": "sci-hub",
  "retrieved_at": "2025-01-05T18:51:12Z"
}